HSDT Helius Medical Technologies Inc. Class A

Helius Medical Technologies, Inc., a medical technology company, focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma. The company develops, licenses, or acquires noninvasive platform technologies that amplify the brain's ability to heal itself. It is developing portable neuromodulation stimulator or PoNS, device for the treatment of movement, gait, and balance disorders in patients with traumatic brain injury, and other chronic neurological diseases. Helius Medical Technologies, Inc. has a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command for the development of the PoNS treatment for chronic balance deficits related to mild-to moderate traumatic brain injury. The company is headquartered in Newtown, Pennsylvania.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:HSM.

$15.91
As of 07/23/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  Canada
Country of incorporation:  USA
IPO date:  06/27/2014
Outstanding shares:  2,317,296
Average volume:  7,232
Market cap:   $37,262,120
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    42328V603
ISIN:        US42328V6039
Sedol:      BMXLWX0
Valuation   (See tab for details)
PE ratio:   -2.90
PB ratio:   46.66
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy